Skip to main content
. Author manuscript; available in PMC: 2023 Mar 21.
Published in final edited form as: J Med Chem. 2019 Mar 5;62(5):2598–2617. doi: 10.1021/acs.jmedchem.8b01927

Figure 6:

Figure 6:

Comparative EGFR signal inhibition efficacy of erlotinib, PS 1 and the corresponding erlotinib conjugates 3 & 5 in bladder cancer cell lines UMUC-3 and T24 cell lines known for high and low expression of EGFR. (A) PS-erlotinib conjugates were treated at 1 µM concentration for 24 hours followed by PDT. (B) UM-UC-3 cells were treated with PS-erlotinib conjugates at 100 nM concentration for 24 hours.